News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN) Said to Push for Lower Onyx Pharmaceuticals, Inc. (ONXX) Price Amid Drug-Data Dispute



8/23/2013 7:29:54 AM

free biotech news Get the latest biotech news where 

you want it. Sign up for the free GenePool newsletter today!

Amgen Inc. (AMGN) is pushing to pay less than the $130 a share it offered this month for Onyx Pharmaceuticals Inc. (ONXX) after failing to obtain requested clinical trial data, said people with knowledge of the matter. Onyx refused to give Amgen additional data on blood-cancer treatment Kyprolis, said one of the people, who asked not to be named because the process is private. Amgen wanted the information to more accurately value the drug, people familiar with the situation said last week.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES